Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from GENinCode UK Ltd. ( (GB:GENI) ).
GENinCode has announced the inclusion of its CARDIO inCode test in the US CMS 2025 Clinical Lab Fee Schedule, facilitating Medicare and Medicaid reimbursement and marking a significant step in US expansion. Additionally, the company is launching CARDIO inCode in Catalonia, Spain, aiming to improve cardiovascular disease risk assessment in primary care, with plans for further expansion in Spanish regions, underscoring its global impact on heart disease prevention.
More about GENinCode UK Ltd.
GENinCode Plc is a UK-based company specializing in genetic risk assessment for cardiovascular disease prevention. The company operates in the UK, Europe, and the United States, utilizing predictive technology with in vitro diagnostic molecular tests to provide advanced patient risk assessment strategies.
YTD Price Performance: -15.79%
Average Trading Volume: 64,479
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £5.66M
For detailed information about GENI stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money